PT  - JOURNAL ARTICLE
AU  - Bonstingl, Lilli
AU  - Skofler, Christina
AU  - Ulz, Christine
AU  - Zinnegger, Margret
AU  - Sallinger, Katja
AU  - Schönberger, Julia
AU  - Schuch, Katharina
AU  - Pankratz, Karin
AU  - Borrás-Cherrier, Anatol
AU  - Somodi, Visnja
AU  - Abuja, Peter M.
AU  - Oberauner-Wappis, Lisa
AU  - Bauernhofer, Thomas
AU  - Kroneis, Thomas
AU  - El-Heliebi, Amin
TI  - Clinical application of ISO and CEN/TS standards for liquid biopsies - information everybody wants but nobody wants to pay for
AID  - 10.1101/2023.12.04.23299422
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.04.23299422
4099  - http://medrxiv.org/content/early/2023/12/05/2023.12.04.23299422.short
4100  - http://medrxiv.org/content/early/2023/12/05/2023.12.04.23299422.full
AB  - Background Liquid biopsies are emerging as valuable clinical biomarkers for cancer monitoring. Despite increasing clinical use, standardization remains a challenge. ISO and CEN/TS standardized workflows exist, but their integration into clinical practice is underdeveloped. We aimed to assess the applicability of ISO and CEN/TS liquid biopsy standards in a real-world clinical setting.Methods We evaluated 659 peripheral blood samples from advanced prostate cancer patients against ISO and CEN/TS standards and tracked all essential criteria. This included assessing tube filing level, complete timing from blood draw until storage, transport conditions, temperature control, hemolysis score and tube draw order and its effects on hemolysis.Results Among 659 samples, 92.4% (609/659) met the essential criteria for ISO and CEN/TS compliance. In total 83.8% (552/659) of blood collection tubes had high fill levels above 80% of nominal filing level. In our advanced prostate cancer cohort, 12.9% (40/311) of the evaluated plasma samples were hemolytic. Within the draw order of five blood collection tubes, hemolysis did not significantly increase from tube one to five. The complete ccfDNA ISO and CTC CEN/TS workflows were completed within an average of 168 (+/- 71 min) and 248 minutes (+/- 76 min), respectively, from blood draw until storage.Conclusions Our study demonstrates the feasibility and benefits of adhering to ISO and CEN/T standards in a clinical liquid biopsy study. ISO and CEN/TS standards revealed that hemolysis is a common phenomenon in pre-treated advanced prostate cancer patients, as we eliminated pre-analytical errors as cause.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLB was supported by the PhD Program AMBRA (Advanced medical biomarker research) of the Medical University of Graz together with the FFG K1 center CBmed (Center for Biomarker Research in Medicine). KS was supported by the Doctoral School Translational Molecular and Cellular Biosciences of the Medical University of Graz and CBmed. This work was supported by the K1 COMET Competence Center CBmed, which is funded by the Federal Ministry of Transport, Innovation and Technology (BMVIT); the Federal Ministry of Science, Research and Economy (BMWFW), Land Steiermark (Department 12, Business and Innovation), the Styrian Business Promotion Agency (SFG), and the Vienna Business Agency. The COMET program is executed by the Austrian Research Promotion Agency (FFG). The research was supported by a grant of the Verein fuer Krebskranke of the Medical University of Graz (Austria) and by MEFO Graz, the Medical Research Funding Society of the Medical University of Graz (Austria).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Medical University of Graz gave ethical approval for this study protocol and patient information (31-353 ex 18/19) following the declaration of Helsinki and good clinical practice, and written informed consent was obtained from all patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript